nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CYP3A4—prostate cancer	0.171	1	CbGaD
Fesoterodine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0483	0.0948	CbGbCtD
Fesoterodine—CYP2D6—Bicalutamide—prostate cancer	0.0399	0.0783	CbGbCtD
Fesoterodine—ABCB1—Estramustine—prostate cancer	0.0394	0.0773	CbGbCtD
Fesoterodine—CYP2D6—Abiraterone—prostate cancer	0.0331	0.0649	CbGbCtD
Fesoterodine—ABCB1—Cabazitaxel—prostate cancer	0.026	0.0509	CbGbCtD
Fesoterodine—CYP3A4—Bicalutamide—prostate cancer	0.0254	0.0498	CbGbCtD
Fesoterodine—ABCB1—Estrone—prostate cancer	0.0254	0.0498	CbGbCtD
Fesoterodine—CYP3A4—Estramustine—prostate cancer	0.0236	0.0463	CbGbCtD
Fesoterodine—ABCB1—Ethinyl Estradiol—prostate cancer	0.0226	0.0444	CbGbCtD
Fesoterodine—CYP3A4—Flutamide—prostate cancer	0.021	0.0413	CbGbCtD
Fesoterodine—CYP3A4—Abiraterone—prostate cancer	0.021	0.0413	CbGbCtD
Fesoterodine—ABCB1—Conjugated Estrogens—prostate cancer	0.0166	0.0326	CbGbCtD
Fesoterodine—CYP3A4—Cabazitaxel—prostate cancer	0.0156	0.0305	CbGbCtD
Fesoterodine—CYP3A4—Estrone—prostate cancer	0.0152	0.0298	CbGbCtD
Fesoterodine—ABCB1—Mitoxantrone—prostate cancer	0.0151	0.0296	CbGbCtD
Fesoterodine—ABCB1—Estradiol—prostate cancer	0.0146	0.0286	CbGbCtD
Fesoterodine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0136	0.0266	CbGbCtD
Fesoterodine—CHRM3—ureter—prostate cancer	0.0125	0.388	CbGeAlD
Fesoterodine—ABCB1—Prednisone—prostate cancer	0.0125	0.0246	CbGbCtD
Fesoterodine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00995	0.0195	CbGbCtD
Fesoterodine—ABCB1—Etoposide—prostate cancer	0.00952	0.0187	CbGbCtD
Fesoterodine—CYP3A4—Mitoxantrone—prostate cancer	0.00905	0.0177	CbGbCtD
Fesoterodine—CYP3A4—Estradiol—prostate cancer	0.00874	0.0171	CbGbCtD
Fesoterodine—ABCB1—Docetaxel—prostate cancer	0.00871	0.0171	CbGbCtD
Fesoterodine—CYP3A4—Prednisone—prostate cancer	0.00751	0.0147	CbGbCtD
Fesoterodine—ABCB1—Doxorubicin—prostate cancer	0.00649	0.0127	CbGbCtD
Fesoterodine—CYP2D6—Doxorubicin—prostate cancer	0.00612	0.012	CbGbCtD
Fesoterodine—CYP3A4—Etoposide—prostate cancer	0.0057	0.0112	CbGbCtD
Fesoterodine—CYP3A4—Docetaxel—prostate cancer	0.00522	0.0102	CbGbCtD
Fesoterodine—CYP3A4—Doxorubicin—prostate cancer	0.00389	0.00763	CbGbCtD
Fesoterodine—CYP3A4—urine—prostate cancer	0.00224	0.0693	CbGeAlD
Fesoterodine—CYP2D6—urine—prostate cancer	0.0022	0.0682	CbGeAlD
Fesoterodine—CHRM5—epithelium—prostate cancer	0.00192	0.0595	CbGeAlD
Fesoterodine—CHRM2—prostate gland—prostate cancer	0.0018	0.0556	CbGeAlD
Fesoterodine—CHRM1—prostate gland—prostate cancer	0.00163	0.0506	CbGeAlD
Fesoterodine—CHRM4—testis—prostate cancer	0.00147	0.0457	CbGeAlD
Fesoterodine—CHRM3—prostate gland—prostate cancer	0.00146	0.0453	CbGeAlD
Fesoterodine—CHRM3—renal system—prostate cancer	0.000997	0.0309	CbGeAlD
Fesoterodine—CHRM3—urethra—prostate cancer	0.000979	0.0303	CbGeAlD
Fesoterodine—Disopyramide—SLC22A1—prostate cancer	0.000952	0.445	CrCbGaD
Fesoterodine—CHRM3—testis—prostate cancer	0.000644	0.02	CbGeAlD
Fesoterodine—ABCB1—prostate gland—prostate cancer	0.000569	0.0176	CbGeAlD
Fesoterodine—CYP3A4—renal system—prostate cancer	0.000548	0.017	CbGeAlD
Fesoterodine—CYP2D6—renal system—prostate cancer	0.000539	0.0167	CbGeAlD
Fesoterodine—Tolterodine—CYP2C19—prostate cancer	0.000523	0.244	CrCbGaD
Fesoterodine—ABCB1—seminal vesicle—prostate cancer	0.000481	0.0149	CbGeAlD
Fesoterodine—ABCB1—epithelium—prostate cancer	0.000418	0.0129	CbGeAlD
Fesoterodine—ABCB1—renal system—prostate cancer	0.000388	0.012	CbGeAlD
Fesoterodine—ABCB1—urethra—prostate cancer	0.000381	0.0118	CbGeAlD
Fesoterodine—CYP2D6—testis—prostate cancer	0.000348	0.0108	CbGeAlD
Fesoterodine—Disopyramide—CYP3A4—prostate cancer	0.000333	0.155	CrCbGaD
Fesoterodine—Tolterodine—CYP3A4—prostate cancer	0.000333	0.155	CrCbGaD
Fesoterodine—ABCB1—bone marrow—prostate cancer	0.000293	0.00908	CbGeAlD
Fesoterodine—ABCB1—testis—prostate cancer	0.000251	0.00776	CbGeAlD
Fesoterodine—ABCB1—lymph node—prostate cancer	0.000182	0.00563	CbGeAlD
Fesoterodine—Chest pain—Etoposide—prostate cancer	0.00015	0.000797	CcSEcCtD
Fesoterodine—Abdominal pain upper—Epirubicin—prostate cancer	0.00015	0.000796	CcSEcCtD
Fesoterodine—Fatigue—Mitoxantrone—prostate cancer	0.000149	0.000792	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000149	0.000792	CcSEcCtD
Fesoterodine—Constipation—Mitoxantrone—prostate cancer	0.000148	0.000786	CcSEcCtD
Fesoterodine—Rash—Goserelin—prostate cancer	0.000148	0.000784	CcSEcCtD
Fesoterodine—Dermatitis—Goserelin—prostate cancer	0.000147	0.000784	CcSEcCtD
Fesoterodine—Urticaria—Estradiol—prostate cancer	0.000147	0.000783	CcSEcCtD
Fesoterodine—Mental disorder—Docetaxel—prostate cancer	0.000147	0.000783	CcSEcCtD
Fesoterodine—Mediastinal disorder—Capecitabine—prostate cancer	0.000147	0.00078	CcSEcCtD
Fesoterodine—Abdominal pain—Estradiol—prostate cancer	0.000147	0.00078	CcSEcCtD
Fesoterodine—Headache—Goserelin—prostate cancer	0.000147	0.000779	CcSEcCtD
Fesoterodine—Face oedema—Doxorubicin—prostate cancer	0.000146	0.000779	CcSEcCtD
Fesoterodine—Rash—Conjugated Estrogens—prostate cancer	0.000146	0.000777	CcSEcCtD
Fesoterodine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000146	0.000776	CcSEcCtD
Fesoterodine—Headache—Conjugated Estrogens—prostate cancer	0.000145	0.000772	CcSEcCtD
Fesoterodine—Confusional state—Etoposide—prostate cancer	0.000145	0.000771	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.000145	0.000769	CcSEcCtD
Fesoterodine—Dysgeusia—Docetaxel—prostate cancer	0.000143	0.000762	CcSEcCtD
Fesoterodine—Infection—Etoposide—prostate cancer	0.000143	0.000759	CcSEcCtD
Fesoterodine—Mental disorder—Capecitabine—prostate cancer	0.000143	0.000758	CcSEcCtD
Fesoterodine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000142	0.000757	CcSEcCtD
Fesoterodine—Back pain—Docetaxel—prostate cancer	0.000142	0.000753	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000141	0.000751	CcSEcCtD
Fesoterodine—Tachycardia—Etoposide—prostate cancer	0.00014	0.000746	CcSEcCtD
Fesoterodine—Flatulence—Capecitabine—prostate cancer	0.00014	0.000742	CcSEcCtD
Fesoterodine—Skin disorder—Etoposide—prostate cancer	0.00014	0.000742	CcSEcCtD
Fesoterodine—Dry skin—Doxorubicin—prostate cancer	0.000139	0.000739	CcSEcCtD
Fesoterodine—Nausea—Goserelin—prostate cancer	0.000139	0.000739	CcSEcCtD
Fesoterodine—Dysgeusia—Capecitabine—prostate cancer	0.000139	0.000738	CcSEcCtD
Fesoterodine—Abdominal pain upper—Doxorubicin—prostate cancer	0.000139	0.000737	CcSEcCtD
Fesoterodine—Angina pectoris—Epirubicin—prostate cancer	0.000138	0.000734	CcSEcCtD
Fesoterodine—Nausea—Conjugated Estrogens—prostate cancer	0.000138	0.000732	CcSEcCtD
Fesoterodine—Urticaria—Mitoxantrone—prostate cancer	0.000137	0.00073	CcSEcCtD
Fesoterodine—Back pain—Capecitabine—prostate cancer	0.000137	0.000729	CcSEcCtD
Fesoterodine—Hypersensitivity—Estradiol—prostate cancer	0.000137	0.000727	CcSEcCtD
Fesoterodine—Abdominal pain—Mitoxantrone—prostate cancer	0.000137	0.000726	CcSEcCtD
Fesoterodine—Eye disorder—Prednisone—prostate cancer	0.000136	0.000721	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Doxorubicin—prostate cancer	0.000134	0.000711	CcSEcCtD
Fesoterodine—Vision blurred—Capecitabine—prostate cancer	0.000134	0.00071	CcSEcCtD
Fesoterodine—Asthenia—Estradiol—prostate cancer	0.000133	0.000708	CcSEcCtD
Fesoterodine—Dysuria—Epirubicin—prostate cancer	0.000133	0.000704	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000132	0.0007	CcSEcCtD
Fesoterodine—Pruritus—Estradiol—prostate cancer	0.000131	0.000698	CcSEcCtD
Fesoterodine—Palpitations—Docetaxel—prostate cancer	0.000129	0.000688	CcSEcCtD
Fesoterodine—Somnolence—Etoposide—prostate cancer	0.000128	0.000679	CcSEcCtD
Fesoterodine—Cough—Docetaxel—prostate cancer	0.000128	0.000679	CcSEcCtD
Fesoterodine—Angina pectoris—Doxorubicin—prostate cancer	0.000128	0.000679	CcSEcCtD
Fesoterodine—Vertigo—Capecitabine—prostate cancer	0.000127	0.000677	CcSEcCtD
Fesoterodine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000127	0.000677	CcSEcCtD
Fesoterodine—Mental disorder—Prednisone—prostate cancer	0.000127	0.000675	CcSEcCtD
Fesoterodine—Diarrhoea—Estradiol—prostate cancer	0.000127	0.000675	CcSEcCtD
Fesoterodine—Infestation NOS—Epirubicin—prostate cancer	0.000126	0.000672	CcSEcCtD
Fesoterodine—Infestation—Epirubicin—prostate cancer	0.000126	0.000672	CcSEcCtD
Fesoterodine—Palpitations—Capecitabine—prostate cancer	0.000125	0.000666	CcSEcCtD
Fesoterodine—Chest pain—Docetaxel—prostate cancer	0.000125	0.000663	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000124	0.00066	CcSEcCtD
Fesoterodine—Asthenia—Mitoxantrone—prostate cancer	0.000124	0.000659	CcSEcCtD
Fesoterodine—Fatigue—Etoposide—prostate cancer	0.000124	0.000659	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000124	0.000658	CcSEcCtD
Fesoterodine—Cough—Capecitabine—prostate cancer	0.000124	0.000658	CcSEcCtD
Fesoterodine—Constipation—Etoposide—prostate cancer	0.000123	0.000654	CcSEcCtD
Fesoterodine—Urinary tract infection—Epirubicin—prostate cancer	0.000123	0.000653	CcSEcCtD
Fesoterodine—Dizziness—Estradiol—prostate cancer	0.000123	0.000652	CcSEcCtD
Fesoterodine—Dysuria—Doxorubicin—prostate cancer	0.000123	0.000652	CcSEcCtD
Fesoterodine—Dry mouth—Docetaxel—prostate cancer	0.000122	0.000648	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000122	0.000648	CcSEcCtD
Fesoterodine—Chest pain—Capecitabine—prostate cancer	0.000121	0.000641	CcSEcCtD
Fesoterodine—Confusional state—Docetaxel—prostate cancer	0.00012	0.00064	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.00012	0.000637	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Epirubicin—prostate cancer	0.00012	0.000635	CcSEcCtD
Fesoterodine—Vision blurred—Prednisone—prostate cancer	0.000119	0.000633	CcSEcCtD
Fesoterodine—Infection—Docetaxel—prostate cancer	0.000119	0.000631	CcSEcCtD
Fesoterodine—Feeling abnormal—Etoposide—prostate cancer	0.000118	0.00063	CcSEcCtD
Fesoterodine—Diarrhoea—Mitoxantrone—prostate cancer	0.000118	0.000629	CcSEcCtD
Fesoterodine—Dry mouth—Capecitabine—prostate cancer	0.000118	0.000627	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Etoposide—prostate cancer	0.000118	0.000625	CcSEcCtD
Fesoterodine—Nervous system disorder—Docetaxel—prostate cancer	0.000117	0.000623	CcSEcCtD
Fesoterodine—Rash—Estradiol—prostate cancer	0.000117	0.000622	CcSEcCtD
Fesoterodine—Infestation NOS—Doxorubicin—prostate cancer	0.000117	0.000622	CcSEcCtD
Fesoterodine—Infestation—Doxorubicin—prostate cancer	0.000117	0.000622	CcSEcCtD
Fesoterodine—Dermatitis—Estradiol—prostate cancer	0.000117	0.000621	CcSEcCtD
Fesoterodine—Confusional state—Capecitabine—prostate cancer	0.000117	0.00062	CcSEcCtD
Fesoterodine—Tachycardia—Docetaxel—prostate cancer	0.000117	0.00062	CcSEcCtD
Fesoterodine—Headache—Estradiol—prostate cancer	0.000116	0.000618	CcSEcCtD
Fesoterodine—Skin disorder—Docetaxel—prostate cancer	0.000116	0.000617	CcSEcCtD
Fesoterodine—Angioedema—Prednisone—prostate cancer	0.000115	0.000613	CcSEcCtD
Fesoterodine—Infection—Capecitabine—prostate cancer	0.000115	0.000611	CcSEcCtD
Fesoterodine—Urticaria—Etoposide—prostate cancer	0.000114	0.000607	CcSEcCtD
Fesoterodine—Abdominal pain—Etoposide—prostate cancer	0.000114	0.000604	CcSEcCtD
Fesoterodine—Urinary tract infection—Doxorubicin—prostate cancer	0.000114	0.000604	CcSEcCtD
Fesoterodine—Nervous system disorder—Capecitabine—prostate cancer	0.000113	0.000603	CcSEcCtD
Fesoterodine—Vertigo—Prednisone—prostate cancer	0.000113	0.000603	CcSEcCtD
Fesoterodine—Tachycardia—Capecitabine—prostate cancer	0.000113	0.0006	CcSEcCtD
Fesoterodine—Skin disorder—Capecitabine—prostate cancer	0.000112	0.000597	CcSEcCtD
Fesoterodine—Urinary tract disorder—Epirubicin—prostate cancer	0.000112	0.000596	CcSEcCtD
Fesoterodine—Oedema peripheral—Epirubicin—prostate cancer	0.000112	0.000594	CcSEcCtD
Fesoterodine—Urethral disorder—Epirubicin—prostate cancer	0.000111	0.000591	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000111	0.000588	CcSEcCtD
Fesoterodine—Nausea—Estradiol—prostate cancer	0.00011	0.000586	CcSEcCtD
Fesoterodine—Rash—Mitoxantrone—prostate cancer	0.000109	0.000579	CcSEcCtD
Fesoterodine—Dermatitis—Mitoxantrone—prostate cancer	0.000109	0.000579	CcSEcCtD
Fesoterodine—Headache—Mitoxantrone—prostate cancer	0.000108	0.000576	CcSEcCtD
Fesoterodine—Insomnia—Docetaxel—prostate cancer	0.000108	0.000574	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000107	0.000567	CcSEcCtD
Fesoterodine—Somnolence—Docetaxel—prostate cancer	0.000106	0.000565	CcSEcCtD
Fesoterodine—Eye disorder—Epirubicin—prostate cancer	0.000106	0.000564	CcSEcCtD
Fesoterodine—Hypersensitivity—Etoposide—prostate cancer	0.000106	0.000563	CcSEcCtD
Fesoterodine—Cardiac disorder—Epirubicin—prostate cancer	0.000105	0.00056	CcSEcCtD
Fesoterodine—Dyspepsia—Docetaxel—prostate cancer	0.000105	0.000559	CcSEcCtD
Fesoterodine—Insomnia—Capecitabine—prostate cancer	0.000105	0.000556	CcSEcCtD
Fesoterodine—Urinary tract disorder—Doxorubicin—prostate cancer	0.000104	0.000551	CcSEcCtD
Fesoterodine—Oedema peripheral—Doxorubicin—prostate cancer	0.000103	0.00055	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000103	0.000548	CcSEcCtD
Fesoterodine—Asthenia—Etoposide—prostate cancer	0.000103	0.000548	CcSEcCtD
Fesoterodine—Fatigue—Docetaxel—prostate cancer	0.000103	0.000548	CcSEcCtD
Fesoterodine—Urethral disorder—Doxorubicin—prostate cancer	0.000103	0.000547	CcSEcCtD
Fesoterodine—Nausea—Mitoxantrone—prostate cancer	0.000103	0.000546	CcSEcCtD
Fesoterodine—Infection—Prednisone—prostate cancer	0.000102	0.000544	CcSEcCtD
Fesoterodine—Mediastinal disorder—Epirubicin—prostate cancer	0.000102	0.000543	CcSEcCtD
Fesoterodine—Constipation—Docetaxel—prostate cancer	0.000102	0.000543	CcSEcCtD
Fesoterodine—Dyspepsia—Capecitabine—prostate cancer	0.000102	0.000541	CcSEcCtD
Fesoterodine—Pruritus—Etoposide—prostate cancer	0.000102	0.000541	CcSEcCtD
Fesoterodine—Nervous system disorder—Prednisone—prostate cancer	0.000101	0.000537	CcSEcCtD
Fesoterodine—Tachycardia—Prednisone—prostate cancer	0.000101	0.000535	CcSEcCtD
Fesoterodine—Skin disorder—Prednisone—prostate cancer	0.0001	0.000532	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Capecitabine—prostate cancer	9.99e-05	0.000531	CcSEcCtD
Fesoterodine—Fatigue—Capecitabine—prostate cancer	9.97e-05	0.00053	CcSEcCtD
Fesoterodine—Mental disorder—Epirubicin—prostate cancer	9.94e-05	0.000528	CcSEcCtD
Fesoterodine—Constipation—Capecitabine—prostate cancer	9.89e-05	0.000526	CcSEcCtD
Fesoterodine—Feeling abnormal—Docetaxel—prostate cancer	9.85e-05	0.000523	CcSEcCtD
Fesoterodine—Diarrhoea—Etoposide—prostate cancer	9.84e-05	0.000523	CcSEcCtD
Fesoterodine—Eye disorder—Doxorubicin—prostate cancer	9.81e-05	0.000521	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Docetaxel—prostate cancer	9.77e-05	0.000519	CcSEcCtD
Fesoterodine—Cardiac disorder—Doxorubicin—prostate cancer	9.74e-05	0.000518	CcSEcCtD
Fesoterodine—Flatulence—Epirubicin—prostate cancer	9.73e-05	0.000517	CcSEcCtD
Fesoterodine—Dysgeusia—Epirubicin—prostate cancer	9.67e-05	0.000514	CcSEcCtD
Fesoterodine—Back pain—Epirubicin—prostate cancer	9.55e-05	0.000508	CcSEcCtD
Fesoterodine—Feeling abnormal—Capecitabine—prostate cancer	9.53e-05	0.000507	CcSEcCtD
Fesoterodine—Dizziness—Etoposide—prostate cancer	9.51e-05	0.000505	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Capecitabine—prostate cancer	9.46e-05	0.000503	CcSEcCtD
Fesoterodine—Mediastinal disorder—Doxorubicin—prostate cancer	9.46e-05	0.000503	CcSEcCtD
Fesoterodine—Abdominal pain—Docetaxel—prostate cancer	9.45e-05	0.000502	CcSEcCtD
Fesoterodine—Insomnia—Prednisone—prostate cancer	9.32e-05	0.000495	CcSEcCtD
Fesoterodine—Vision blurred—Epirubicin—prostate cancer	9.31e-05	0.000495	CcSEcCtD
Fesoterodine—Mental disorder—Doxorubicin—prostate cancer	9.2e-05	0.000489	CcSEcCtD
Fesoterodine—Urticaria—Capecitabine—prostate cancer	9.19e-05	0.000489	CcSEcCtD
Fesoterodine—Abdominal pain—Capecitabine—prostate cancer	9.15e-05	0.000486	CcSEcCtD
Fesoterodine—Dyspepsia—Prednisone—prostate cancer	9.07e-05	0.000482	CcSEcCtD
Fesoterodine—Rash—Etoposide—prostate cancer	9.07e-05	0.000482	CcSEcCtD
Fesoterodine—Dermatitis—Etoposide—prostate cancer	9.06e-05	0.000481	CcSEcCtD
Fesoterodine—Headache—Etoposide—prostate cancer	9.01e-05	0.000479	CcSEcCtD
Fesoterodine—Flatulence—Doxorubicin—prostate cancer	9e-05	0.000479	CcSEcCtD
Fesoterodine—Dysgeusia—Doxorubicin—prostate cancer	8.95e-05	0.000476	CcSEcCtD
Fesoterodine—Fatigue—Prednisone—prostate cancer	8.89e-05	0.000472	CcSEcCtD
Fesoterodine—Vertigo—Epirubicin—prostate cancer	8.87e-05	0.000472	CcSEcCtD
Fesoterodine—Back pain—Doxorubicin—prostate cancer	8.84e-05	0.00047	CcSEcCtD
Fesoterodine—Constipation—Prednisone—prostate cancer	8.81e-05	0.000468	CcSEcCtD
Fesoterodine—Hypersensitivity—Docetaxel—prostate cancer	8.8e-05	0.000468	CcSEcCtD
Fesoterodine—Palpitations—Epirubicin—prostate cancer	8.73e-05	0.000464	CcSEcCtD
Fesoterodine—Cough—Epirubicin—prostate cancer	8.62e-05	0.000458	CcSEcCtD
Fesoterodine—Vision blurred—Doxorubicin—prostate cancer	8.61e-05	0.000458	CcSEcCtD
Fesoterodine—Asthenia—Docetaxel—prostate cancer	8.57e-05	0.000456	CcSEcCtD
Fesoterodine—Nausea—Etoposide—prostate cancer	8.54e-05	0.000454	CcSEcCtD
Fesoterodine—Hypersensitivity—Capecitabine—prostate cancer	8.52e-05	0.000453	CcSEcCtD
Fesoterodine—Feeling abnormal—Prednisone—prostate cancer	8.49e-05	0.000451	CcSEcCtD
Fesoterodine—Pruritus—Docetaxel—prostate cancer	8.45e-05	0.000449	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Prednisone—prostate cancer	8.43e-05	0.000448	CcSEcCtD
Fesoterodine—Chest pain—Epirubicin—prostate cancer	8.41e-05	0.000447	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	8.35e-05	0.000444	CcSEcCtD
Fesoterodine—Asthenia—Capecitabine—prostate cancer	8.3e-05	0.000441	CcSEcCtD
Fesoterodine—Dry mouth—Epirubicin—prostate cancer	8.22e-05	0.000437	CcSEcCtD
Fesoterodine—Vertigo—Doxorubicin—prostate cancer	8.21e-05	0.000436	CcSEcCtD
Fesoterodine—Urticaria—Prednisone—prostate cancer	8.19e-05	0.000435	CcSEcCtD
Fesoterodine—Pruritus—Capecitabine—prostate cancer	8.19e-05	0.000435	CcSEcCtD
Fesoterodine—Diarrhoea—Docetaxel—prostate cancer	8.18e-05	0.000435	CcSEcCtD
Fesoterodine—Abdominal pain—Prednisone—prostate cancer	8.15e-05	0.000433	CcSEcCtD
Fesoterodine—Confusional state—Epirubicin—prostate cancer	8.13e-05	0.000432	CcSEcCtD
Fesoterodine—Palpitations—Doxorubicin—prostate cancer	8.08e-05	0.000429	CcSEcCtD
Fesoterodine—Infection—Epirubicin—prostate cancer	8.01e-05	0.000426	CcSEcCtD
Fesoterodine—Cough—Doxorubicin—prostate cancer	7.97e-05	0.000424	CcSEcCtD
Fesoterodine—Diarrhoea—Capecitabine—prostate cancer	7.92e-05	0.000421	CcSEcCtD
Fesoterodine—Nervous system disorder—Epirubicin—prostate cancer	7.9e-05	0.00042	CcSEcCtD
Fesoterodine—Dizziness—Docetaxel—prostate cancer	7.9e-05	0.00042	CcSEcCtD
Fesoterodine—Tachycardia—Epirubicin—prostate cancer	7.87e-05	0.000418	CcSEcCtD
Fesoterodine—Skin disorder—Epirubicin—prostate cancer	7.83e-05	0.000416	CcSEcCtD
Fesoterodine—Chest pain—Doxorubicin—prostate cancer	7.78e-05	0.000414	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	7.73e-05	0.000411	CcSEcCtD
Fesoterodine—Dizziness—Capecitabine—prostate cancer	7.65e-05	0.000407	CcSEcCtD
Fesoterodine—Dry mouth—Doxorubicin—prostate cancer	7.61e-05	0.000404	CcSEcCtD
Fesoterodine—Hypersensitivity—Prednisone—prostate cancer	7.59e-05	0.000404	CcSEcCtD
Fesoterodine—Rash—Docetaxel—prostate cancer	7.53e-05	0.0004	CcSEcCtD
Fesoterodine—Dermatitis—Docetaxel—prostate cancer	7.53e-05	0.0004	CcSEcCtD
Fesoterodine—Confusional state—Doxorubicin—prostate cancer	7.52e-05	0.0004	CcSEcCtD
Fesoterodine—Headache—Docetaxel—prostate cancer	7.49e-05	0.000398	CcSEcCtD
Fesoterodine—Infection—Doxorubicin—prostate cancer	7.41e-05	0.000394	CcSEcCtD
Fesoterodine—Asthenia—Prednisone—prostate cancer	7.39e-05	0.000393	CcSEcCtD
Fesoterodine—Nervous system disorder—Doxorubicin—prostate cancer	7.31e-05	0.000389	CcSEcCtD
Fesoterodine—Rash—Capecitabine—prostate cancer	7.29e-05	0.000388	CcSEcCtD
Fesoterodine—Pruritus—Prednisone—prostate cancer	7.29e-05	0.000388	CcSEcCtD
Fesoterodine—Insomnia—Epirubicin—prostate cancer	7.29e-05	0.000387	CcSEcCtD
Fesoterodine—Dermatitis—Capecitabine—prostate cancer	7.29e-05	0.000387	CcSEcCtD
Fesoterodine—Tachycardia—Doxorubicin—prostate cancer	7.28e-05	0.000387	CcSEcCtD
Fesoterodine—Headache—Capecitabine—prostate cancer	7.25e-05	0.000385	CcSEcCtD
Fesoterodine—Skin disorder—Doxorubicin—prostate cancer	7.24e-05	0.000385	CcSEcCtD
Fesoterodine—Somnolence—Epirubicin—prostate cancer	7.17e-05	0.000381	CcSEcCtD
Fesoterodine—Nausea—Docetaxel—prostate cancer	7.1e-05	0.000377	CcSEcCtD
Fesoterodine—Dyspepsia—Epirubicin—prostate cancer	7.1e-05	0.000377	CcSEcCtD
Fesoterodine—Diarrhoea—Prednisone—prostate cancer	7.05e-05	0.000375	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Epirubicin—prostate cancer	6.96e-05	0.00037	CcSEcCtD
Fesoterodine—Fatigue—Epirubicin—prostate cancer	6.95e-05	0.000369	CcSEcCtD
Fesoterodine—Constipation—Epirubicin—prostate cancer	6.89e-05	0.000366	CcSEcCtD
Fesoterodine—Nausea—Capecitabine—prostate cancer	6.87e-05	0.000365	CcSEcCtD
Fesoterodine—Dizziness—Prednisone—prostate cancer	6.81e-05	0.000362	CcSEcCtD
Fesoterodine—Insomnia—Doxorubicin—prostate cancer	6.75e-05	0.000359	CcSEcCtD
Fesoterodine—Feeling abnormal—Epirubicin—prostate cancer	6.64e-05	0.000353	CcSEcCtD
Fesoterodine—Somnolence—Doxorubicin—prostate cancer	6.63e-05	0.000352	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Epirubicin—prostate cancer	6.59e-05	0.00035	CcSEcCtD
Fesoterodine—Dyspepsia—Doxorubicin—prostate cancer	6.56e-05	0.000349	CcSEcCtD
Fesoterodine—Rash—Prednisone—prostate cancer	6.5e-05	0.000345	CcSEcCtD
Fesoterodine—Dermatitis—Prednisone—prostate cancer	6.49e-05	0.000345	CcSEcCtD
Fesoterodine—Headache—Prednisone—prostate cancer	6.46e-05	0.000343	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.44e-05	0.000342	CcSEcCtD
Fesoterodine—Fatigue—Doxorubicin—prostate cancer	6.43e-05	0.000342	CcSEcCtD
Fesoterodine—Urticaria—Epirubicin—prostate cancer	6.4e-05	0.00034	CcSEcCtD
Fesoterodine—Constipation—Doxorubicin—prostate cancer	6.38e-05	0.000339	CcSEcCtD
Fesoterodine—Abdominal pain—Epirubicin—prostate cancer	6.37e-05	0.000339	CcSEcCtD
Fesoterodine—Feeling abnormal—Doxorubicin—prostate cancer	6.15e-05	0.000327	CcSEcCtD
Fesoterodine—Nausea—Prednisone—prostate cancer	6.12e-05	0.000325	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Doxorubicin—prostate cancer	6.1e-05	0.000324	CcSEcCtD
Fesoterodine—Hypersensitivity—Epirubicin—prostate cancer	5.94e-05	0.000316	CcSEcCtD
Fesoterodine—Urticaria—Doxorubicin—prostate cancer	5.92e-05	0.000315	CcSEcCtD
Fesoterodine—Abdominal pain—Doxorubicin—prostate cancer	5.9e-05	0.000313	CcSEcCtD
Fesoterodine—Asthenia—Epirubicin—prostate cancer	5.78e-05	0.000307	CcSEcCtD
Fesoterodine—Pruritus—Epirubicin—prostate cancer	5.7e-05	0.000303	CcSEcCtD
Fesoterodine—Diarrhoea—Epirubicin—prostate cancer	5.51e-05	0.000293	CcSEcCtD
Fesoterodine—Hypersensitivity—Doxorubicin—prostate cancer	5.49e-05	0.000292	CcSEcCtD
Fesoterodine—Asthenia—Doxorubicin—prostate cancer	5.35e-05	0.000284	CcSEcCtD
Fesoterodine—Dizziness—Epirubicin—prostate cancer	5.33e-05	0.000283	CcSEcCtD
Fesoterodine—Pruritus—Doxorubicin—prostate cancer	5.28e-05	0.00028	CcSEcCtD
Fesoterodine—Diarrhoea—Doxorubicin—prostate cancer	5.1e-05	0.000271	CcSEcCtD
Fesoterodine—Rash—Epirubicin—prostate cancer	5.08e-05	0.00027	CcSEcCtD
Fesoterodine—Dermatitis—Epirubicin—prostate cancer	5.08e-05	0.00027	CcSEcCtD
Fesoterodine—Headache—Epirubicin—prostate cancer	5.05e-05	0.000268	CcSEcCtD
Fesoterodine—Dizziness—Doxorubicin—prostate cancer	4.93e-05	0.000262	CcSEcCtD
Fesoterodine—Nausea—Epirubicin—prostate cancer	4.79e-05	0.000254	CcSEcCtD
Fesoterodine—Rash—Doxorubicin—prostate cancer	4.7e-05	0.00025	CcSEcCtD
Fesoterodine—Dermatitis—Doxorubicin—prostate cancer	4.7e-05	0.00025	CcSEcCtD
Fesoterodine—Headache—Doxorubicin—prostate cancer	4.67e-05	0.000248	CcSEcCtD
Fesoterodine—Nausea—Doxorubicin—prostate cancer	4.43e-05	0.000235	CcSEcCtD
Fesoterodine—ABCB1—Metabolism—LPL—prostate cancer	4.74e-06	4.93e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL2—prostate cancer	4.74e-06	4.93e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—APC—prostate cancer	4.73e-06	4.92e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	4.73e-06	4.92e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL6—prostate cancer	4.72e-06	4.9e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—NOS3—prostate cancer	4.69e-06	4.88e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGF—prostate cancer	4.69e-06	4.87e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IRS1—prostate cancer	4.69e-06	4.87e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MMP9—prostate cancer	4.68e-06	4.87e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	4.68e-06	4.87e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—APC—prostate cancer	4.68e-06	4.87e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTT1—prostate cancer	4.67e-06	4.86e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ACHE—prostate cancer	4.67e-06	4.86e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGF—prostate cancer	4.67e-06	4.86e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IRS1—prostate cancer	4.67e-06	4.86e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1A—prostate cancer	4.67e-06	4.85e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PTEN—prostate cancer	4.66e-06	4.84e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IRS1—prostate cancer	4.63e-06	4.81e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGF—prostate cancer	4.63e-06	4.81e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCND1—prostate cancer	4.62e-06	4.8e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.62e-06	4.8e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—TYMS—prostate cancer	4.6e-06	4.79e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CYP1A1—prostate cancer	4.58e-06	4.76e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CTNNB1—prostate cancer	4.57e-06	4.76e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTM1—prostate cancer	4.55e-06	4.73e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—GSK3B—prostate cancer	4.55e-06	4.73e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—AKT1—prostate cancer	4.54e-06	4.72e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ERCC2—prostate cancer	4.54e-06	4.72e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—GSK3B—prostate cancer	4.54e-06	4.72e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.49e-06	4.67e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—GSK3B—prostate cancer	4.49e-06	4.67e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—INS—prostate cancer	4.49e-06	4.67e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—prostate cancer	4.49e-06	4.66e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—INS—prostate cancer	4.47e-06	4.65e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1A—prostate cancer	4.47e-06	4.65e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PRKACB—prostate cancer	4.47e-06	4.65e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—LPL—prostate cancer	4.47e-06	4.65e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PTEN—prostate cancer	4.46e-06	4.64e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EP300—prostate cancer	4.44e-06	4.62e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—INS—prostate cancer	4.43e-06	4.61e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.42e-06	4.6e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CREBBP—prostate cancer	4.4e-06	4.57e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CREBBP—prostate cancer	4.38e-06	4.56e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—AKT1—prostate cancer	4.35e-06	4.52e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IGF1—prostate cancer	4.34e-06	4.52e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CREBBP—prostate cancer	4.34e-06	4.51e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CB—prostate cancer	4.33e-06	4.5e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IGF1—prostate cancer	4.33e-06	4.5e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—EGFR—prostate cancer	4.32e-06	4.49e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SRC—prostate cancer	4.32e-06	4.49e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CYP1A1—prostate cancer	4.32e-06	4.49e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—EGFR—prostate cancer	4.31e-06	4.48e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTGS2—prostate cancer	4.29e-06	4.46e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IGF1—prostate cancer	4.29e-06	4.46e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ERCC2—prostate cancer	4.28e-06	4.45e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—MTHFR—prostate cancer	4.27e-06	4.44e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—EGFR—prostate cancer	4.26e-06	4.44e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EP300—prostate cancer	4.25e-06	4.42e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NCOA2—prostate cancer	4.21e-06	4.38e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—VEGFA—prostate cancer	4.21e-06	4.37e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	4.2e-06	4.36e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PPARA—prostate cancer	4.19e-06	4.36e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	4.18e-06	4.35e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	4.17e-06	4.34e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—STAT3—prostate cancer	4.16e-06	4.33e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	4.16e-06	4.32e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	4.14e-06	4.31e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SRC—prostate cancer	4.14e-06	4.3e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	4.13e-06	4.29e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	4.12e-06	4.29e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	4.12e-06	4.28e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	4.11e-06	4.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	4.11e-06	4.27e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—KRAS—prostate cancer	4.08e-06	4.24e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	4.08e-06	4.24e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	4.07e-06	4.23e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—KRAS—prostate cancer	4.07e-06	4.23e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—KRAS—prostate cancer	4.03e-06	4.19e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—VEGFA—prostate cancer	4.03e-06	4.19e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—MTHFR—prostate cancer	4.02e-06	4.18e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.02e-06	4.18e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—FGF2—prostate cancer	3.99e-06	4.15e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—STAT3—prostate cancer	3.99e-06	4.15e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—FGF2—prostate cancer	3.98e-06	4.14e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PPARA—prostate cancer	3.95e-06	4.1e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—FGF2—prostate cancer	3.94e-06	4.1e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CAV1—prostate cancer	3.94e-06	4.1e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NOS3—prostate cancer	3.94e-06	4.09e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.93e-06	4.08e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NOS3—prostate cancer	3.92e-06	4.08e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NOS3—prostate cancer	3.89e-06	4.04e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NQO1—prostate cancer	3.88e-06	4.04e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MYC—prostate cancer	3.87e-06	4.02e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TGFB1—prostate cancer	3.86e-06	4.01e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—TH—prostate cancer	3.83e-06	3.98e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JAK2—prostate cancer	3.83e-06	3.98e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JAK2—prostate cancer	3.81e-06	3.97e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EGFR—prostate cancer	3.78e-06	3.94e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JAK2—prostate cancer	3.78e-06	3.93e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	3.75e-06	3.9e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTEN—prostate cancer	3.74e-06	3.89e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	3.74e-06	3.89e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MDM2—prostate cancer	3.73e-06	3.88e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.72e-06	3.87e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MDM2—prostate cancer	3.72e-06	3.87e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CAV1—prostate cancer	3.71e-06	3.86e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MYC—prostate cancer	3.71e-06	3.85e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	3.7e-06	3.85e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TGFB1—prostate cancer	3.7e-06	3.84e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MDM2—prostate cancer	3.69e-06	3.83e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ERBB2—prostate cancer	3.68e-06	3.83e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ERBB2—prostate cancer	3.67e-06	3.82e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ERBB2—prostate cancer	3.63e-06	3.78e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	3.63e-06	3.78e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EGFR—prostate cancer	3.62e-06	3.77e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	3.62e-06	3.77e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GGT1—prostate cancer	3.61e-06	3.75e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CG—prostate cancer	3.59e-06	3.73e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	3.59e-06	3.73e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KRAS—prostate cancer	3.58e-06	3.72e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—EP300—prostate cancer	3.57e-06	3.71e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NCOA1—prostate cancer	3.55e-06	3.69e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.5e-06	3.64e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCL8—prostate cancer	3.49e-06	3.63e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCL8—prostate cancer	3.48e-06	3.62e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCL8—prostate cancer	3.45e-06	3.58e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KRAS—prostate cancer	3.42e-06	3.56e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	3.41e-06	3.55e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	3.4e-06	3.54e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—INS—prostate cancer	3.4e-06	3.53e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CG—prostate cancer	3.38e-06	3.52e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—RXRA—prostate cancer	3.38e-06	3.51e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	3.37e-06	3.51e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	3.37e-06	3.5e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	3.36e-06	3.5e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CASP3—prostate cancer	3.34e-06	3.48e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—prostate cancer	3.34e-06	3.47e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CASP3—prostate cancer	3.33e-06	3.46e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	3.33e-06	3.46e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—prostate cancer	3.33e-06	3.46e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CREBBP—prostate cancer	3.33e-06	3.46e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—prostate cancer	3.32e-06	3.45e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—prostate cancer	3.31e-06	3.44e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CASP3—prostate cancer	3.3e-06	3.43e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—prostate cancer	3.29e-06	3.43e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	3.28e-06	3.42e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—prostate cancer	3.28e-06	3.41e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—COMT—prostate cancer	3.25e-06	3.38e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCND1—prostate cancer	3.25e-06	3.38e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCND1—prostate cancer	3.24e-06	3.37e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTP1—prostate cancer	3.24e-06	3.37e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	3.22e-06	3.35e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	3.21e-06	3.34e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCND1—prostate cancer	3.21e-06	3.34e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—INS—prostate cancer	3.2e-06	3.33e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ITPR1—prostate cancer	3.19e-06	3.31e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	3.18e-06	3.31e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—prostate cancer	3.18e-06	3.31e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—prostate cancer	3.16e-06	3.28e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CD—prostate cancer	3.15e-06	3.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—prostate cancer	3.15e-06	3.27e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	3.15e-06	3.27e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	3.15e-06	3.27e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTEN—prostate cancer	3.14e-06	3.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	3.14e-06	3.26e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CREBBP—prostate cancer	3.13e-06	3.26e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTEN—prostate cancer	3.13e-06	3.26e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—prostate cancer	3.12e-06	3.24e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	3.11e-06	3.23e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTEN—prostate cancer	3.1e-06	3.22e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	3.06e-06	3.19e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—AKT1—prostate cancer	3.05e-06	3.18e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—prostate cancer	3.04e-06	3.17e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	3.02e-06	3.14e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—TYMS—prostate cancer	3.01e-06	3.13e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EP300—prostate cancer	2.99e-06	3.11e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EP300—prostate cancer	2.98e-06	3.1e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NOS3—prostate cancer	2.98e-06	3.1e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTM1—prostate cancer	2.98e-06	3.1e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.97e-06	3.09e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EP300—prostate cancer	2.96e-06	3.07e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—LPL—prostate cancer	2.92e-06	3.04e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SRC—prostate cancer	2.91e-06	3.03e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—prostate cancer	2.91e-06	3.03e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SRC—prostate cancer	2.9e-06	3.02e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SRC—prostate cancer	2.87e-06	2.99e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	2.84e-06	2.95e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—VEGFA—prostate cancer	2.83e-06	2.94e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.82e-06	2.93e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—STAT3—prostate cancer	2.81e-06	2.92e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NOS3—prostate cancer	2.81e-06	2.92e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	2.8e-06	2.91e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—STAT3—prostate cancer	2.8e-06	2.91e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ERCC2—prostate cancer	2.8e-06	2.91e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—prostate cancer	2.79e-06	2.9e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—STAT3—prostate cancer	2.77e-06	2.88e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CB—prostate cancer	2.75e-06	2.86e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTGS2—prostate cancer	2.72e-06	2.83e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—AKT1—prostate cancer	2.68e-06	2.79e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CA—prostate cancer	2.64e-06	2.75e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—MTHFR—prostate cancer	2.63e-06	2.74e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MYC—prostate cancer	2.61e-06	2.71e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	2.6e-06	2.71e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MYC—prostate cancer	2.6e-06	2.71e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TGFB1—prostate cancer	2.59e-06	2.7e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CB—prostate cancer	2.59e-06	2.69e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PPARA—prostate cancer	2.58e-06	2.68e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MYC—prostate cancer	2.58e-06	2.68e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—AKT1—prostate cancer	2.57e-06	2.67e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	2.57e-06	2.67e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTGS2—prostate cancer	2.57e-06	2.67e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGFR—prostate cancer	2.55e-06	2.65e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGFR—prostate cancer	2.54e-06	2.65e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGFR—prostate cancer	2.52e-06	2.62e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CAV1—prostate cancer	2.43e-06	2.52e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KRAS—prostate cancer	2.41e-06	2.51e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KRAS—prostate cancer	2.4e-06	2.5e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KRAS—prostate cancer	2.38e-06	2.48e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTEN—prostate cancer	2.37e-06	2.47e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—EP300—prostate cancer	2.26e-06	2.36e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTEN—prostate cancer	2.24e-06	2.33e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	2.21e-06	2.3e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.21e-06	2.3e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	2.21e-06	2.3e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	2.19e-06	2.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AKT1—prostate cancer	2.16e-06	2.24e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—prostate cancer	2.14e-06	2.23e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—prostate cancer	2.14e-06	2.22e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—EP300—prostate cancer	2.13e-06	2.22e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—prostate cancer	2.12e-06	2.2e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—INS—prostate cancer	2.09e-06	2.18e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CREBBP—prostate cancer	2.05e-06	2.13e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—prostate cancer	1.96e-06	2.04e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—prostate cancer	1.96e-06	2.03e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.94e-06	2.02e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—prostate cancer	1.94e-06	2.01e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NOS3—prostate cancer	1.83e-06	1.91e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT1—prostate cancer	1.81e-06	1.88e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT1—prostate cancer	1.8e-06	1.88e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT1—prostate cancer	1.79e-06	1.86e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.69e-06	1.76e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.68e-06	1.74e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CA—prostate cancer	1.68e-06	1.74e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.58e-06	1.64e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTEN—prostate cancer	1.46e-06	1.52e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—EP300—prostate cancer	1.4e-06	1.45e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AKT1—prostate cancer	1.37e-06	1.42e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AKT1—prostate cancer	1.29e-06	1.34e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.03e-06	1.07e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKT1—prostate cancer	8.43e-07	8.77e-06	CbGpPWpGaD
